Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus GRISACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus GRISACTIN.
DIFLUCAN vs GRISACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Category C
Category C
Antifungal
Antifungal